The activities of mitochondrial enzymes, which are essential for neural function, decline with age and in age-related disease. In particular, the activity of cytochrome c oxidase (COX/complex IV) decreases in patients with Alzheimer's disease (AD). COX, a mitochondrial inner membrane protein complex that contains heme, plays an essential role in the electron transport chain that generates ATP. Heme synthesis begins with 5-aminolevulinic acid (5-ALA) in mitochondria. 5-ALA synthetase is the rate-limiting enzyme in heme synthesis, suggesting that supplementation with 5-ALA might help preserve mitochondrial activity in the aged brain. We administered a diet containing 5-ALA to triple-transgenic AD (3xTg-AD) model mice for 6 months, starting at 3 months-of-age. COX activity and protein expression, as well as mitochondrial membrane potential, were significantly higher in brains of 5-ALA-fed mice than in controls. Synaptotagmin protein levels were also significantly higher in 5-ALA-fed mice, suggesting improved preservation of synapses. Although brain Aβ levels tended to decrease in 5-ALA-fed mice, we observed no other significant changes in other biochemical and pathological hallmarks of AD. Nevertheless, our study suggests that daily oral administration of 5-ALA could preserve mitochondrial enzyme activities in the brains of aged individuals, thereby contributing to the preservation of neural activity.
Introduction
In general, mitochondrial activity attenuates with age; consequently, aged individuals have less capacity to produce ATP for use in energy-dependent cellular events.
1, 2 For example, the levels of respiratory chain complexes are reduced in liver mitochondria of aged rats. 3 To perform higher-order brain functions, neurons must consume huge amounts of energy. The levels of cytochrome c oxidase (COX/complex IV) decrease in Alzheimer's disease; 4 this may be related to the diminished cognitive ability of aged subjects. Heme-integrated proteins such as COX, hemoglobin, and myoglobin play fundamental roles in animal physiology, and heme itself serves as a cofactor for multiple enzymes. Thus, heme is a critical for multiple cellular phenomena.
5
The heme molecule is synthesized from the precursor 5-aminolevulinic acid (5-ALA), which in animal cells is produced from glycine and succinyl-CoA via the classical Shemin pathway. 5 5-ALA synthetase is the rate-limiting enzyme in the heme synthesis pathway, suggesting that supplementation with 5-ALA could upregulate heme synthesis and facilitate multiple biological functions by increasing mitochondrial activity. 6 The impairment of neural functions associated with aging may be the result of reduced mitochondrial activity in neurons, potentially contributing to neurodegenerative disorders such as Alzheimer's disease (AD), the most common form of senile dementia.
In other words, preservation of mitochondrial activity may contribute to the maintenance of neural function in aged subjects who develop cognitive impairment.
7, 8
Consistent with this, mitochondrial dysfunction has been reported in mouse models of AD. 9, 10 These observations suggest that prevention of mitochondrial deterioration could slow neurodegeneration in the early or prodromal phase of AD. Thus, supplementation with 5-ALA could be an effective means of preserving or increasing mitochondrial activity in the brains of aged individuals. Although administration of 5-ALA to mice increases COX activity in the liver, 11 it remains unknown whether oral administration of 5-ALA can preserve mitochondrial function in the brain and prevent biological alterations characteristic of neurodegenerative disorders such as AD.
In this study, we analyzed the effect of orally administrated 5-ALA in the brain of triple transgenic AD (3xTg-AD) model mice 12 . First, to characterize general mitochondrial activity in 3xTg-AD mice, we examined mitochondrial COX expression and activity in the hippocampus and cerebral cortex of animals undergoing daily administration of 5-ALA. Second, to explore the effects of 5-ALA on the pathobiology of AD, we analyzed changes in synaptic proteins and proteins known to play causative roles in AD.
Materials and methods

Animals
All animal studies were conducted in compliance with the guidelines of Animal Studies
Committee of Hokkaido University. Triple-transgenic Alzheimer's disease (3xTg-AD)
12
model mice, which harbor the PS1 M146V , APP swe , and tau P301L transgenes, were purchased from Jackson Laboratories. Mice were housed in a specific pathogen-free environment with Allentown MicroVent units throughout these studies. Mice were weaned at 1 month and raised on a commercial diet (PicoLab mouse diet 20, LabDiet, St. Louis, MO, USA) until the age of 3 months. Subsequently, the mice received either a control diet or a diet supplemented with 0.12% (w/w) 5-ALA (chow: Oriental Yeast Co Ltd., Tokyo, Japan; 5-ALA: SBI Pharmaceuticals Co Ltd, Tokyo, Japan). Mice were cultivated for 6 months under free-feeding conditions. During this interval, mice consumed 1.5-2 g of food per day, i.e., 1.8-2.4 mg of 5-ALA per day. At the age of 9 months, the mice were sacrificed and their brains dissected. The brain region encompassing the hippocampus and cerebral cortex was used for all examinations, except for immunohistochemical analysis.
Brain fractionation
The hippocampus and cerebral cortex were homogenized in 10 volumes of extraction buffer (10 mM HEPES [pH 7.5], 200 mM mannitol, 70 mM sucrose, 1 mM EGTA) containing 2 mg/ml bovine serum albumin (BSA) with 25 strokes of a Dounce homogenizer. After the lysate was centrifuged at 600 × g for 10 min, the post-nuclear supernatant (PNS) was further centrifuged at 100,000 × g for 1 h. The precipitated membrane fraction (P100) was used for Western blotting to detect membrane proteins.
PNS was centrifuged at 11,000 × g for 10 min, the supernatant removed, and the precipitate suspended in extraction buffer. The resultant suspension was centrifuged at 600 × g for 5 min and the supernatant further centrifuged at 11,000 × g for 10 min.
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The precipitated fraction was suspended in storage buffer (10 USA), and anti-NR2B (BD Biosciences) antibodies were purchased from the indicated suppliers.
Quantitation of Aβ40 and Aβ42
Aβ quantification was performed as described previously. 16 The resultant supernatant was assayed using appropriate ELISA kits (IBL 27714 for human Aβ40 and IBL 27712 for human Aβ42).
Immunohistochemistry 3xTg-AD mouse brain tissue sections (25 µm thick) were prepared and incubated overnight with the indicated mouse monoclonal antibody, as previously described.
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Immunostained sections were washed in PBS, incubated with a biotin-conjugated horse anti-mouse IgG antibody, and then incubated with ABC complex (Vector Laboratories, Burlingame, CA USA). Peroxidase activity was revealed using diaminobenzidine (DAB) as the chromogen. Images were acquired under a BZ-X710 microscope (KEYENCE, Osaka, Japan).
Statistical analysis
Statistical analyses were performed with GraphPad Prism (GraphPad Software, San Diego, CA, USA). The threshold for significance is indicated with p value (*, p<0.05).
Results
Orally administered 5-ALA activates mitochondria in the hippocampus and cerebral cortex
A previous study shows that oral administration of 5-ALA increases COX activity in the liver of 6-week-old female wild-type C57BL6/N mice 11 . Therefore, we investigated the effect of 5-ALA on COX activity in the mitochondrial fraction of the brain region encompassing the hippocampus and cerebral cortex (Fig. 1A) . COX activity was slightly but significantly elevated in the mitochondrial fractions of 5-ALA-fed mouse brains relative to those of controls. Therefore, we performed Western blotting to examine the COX IV level in the mitochondrial fraction from hippocampus and cerebral cortex ( Fig. 2 , lower rows); COX levels were normalized against the level of voltage-dependent anion-selective channel protein 1 (VDAC1) in the same sample (Fig.   3A ). The COX IV protein level in the mitochondrial fraction increased significantly in mice that received 5-ALA. By contrast, levels of VDAC1, which is localized largely on the outer mitochondrial membrane, were not altered by the administration of 5-ALA (Fig. 3A) . The change in the COX IV level was relatively modest, but had a measurable physiological effect: mitochondrial membrane potential was significantly higher in 5-ALA-fed mice than in control mice (Fig. 1B) . These data indicate that prolonged daily oral administration of 5-ALA can activate mitochondrial function in the brain, at least in the region encompassing the hippocampus and cerebral cortex.
Changes in AD-related and causative proteins in the brain upon 5-ALA administration
The 3xTg-AD model mouse exhibits AD pathologies associated with extracellular Aβ deposits by the age of 6 months. 12 Accordingly, we performed Western blotting to analyzed changes in protein levels, including accumulation of Aβ, in 9-month-old mice that had consumed a diet with or without 5-ALA for 6 months. In this study, we used PNS/cytoplasmic and crude membrane fractions from the brain region encompassing the hippocampus and cerebral cortex.
Because 3xTg-AD mice exhibit cognitive impairment, 17 we first examined the synaptic proteins of 5-ALA-fed and control mice. Specifically, we measured the levels of presynaptic synaptotagmin and postsynaptic PSD95 (Fig. 2) . The synaptotagmin level increased significantly when normalized against actin, but not when normalized against α-tubulin (Fig. 3B) . The level of postsynaptic PSD95 did not change in 5-ALAfed mice relative to controls, irrespective of the choice of normalization control (Figs.
3B).
We also examined the levels of other postsynaptic proteins, including the NR2A and NR2B subunits of the NMDA receptor and the GluR1 subunit of the AMPA receptor (Fig. 2) ; these proteins did not change in 5-ALA-fed mice when compared to controls (Fig. 3C) . Thus, the effect of 5-ALA on synaptic proteins of 9-month-old mice, if any, may be limited. It is thought that in AD neurotoxic Aβ oligomers impair synapses primarily, and that the Aβ accumulation starts prior to change of the levels of synaptic components. (Figs. 2) . Contrary to the findings of the previous original report, 12 the levels of CTFβ, APP, and BACE1 tended to be higher in females than in males. Production of APP CTFβ tended to be higher in the brains of 5-ALA-fed mice, but the difference was not significant (Fig. 3D) . This trend may have been due to the different numbers of females in the 5-ALA-fed and control cohorts rather than to an effect 5-ALA. In the 3xTg-AD mouse, the APP transgene carrying the Swedish mutation expresses two APP species, mature and immature APP, and generates much more CTFβ than CTFα (Fig. 2) . Identification and characterization of the APP FL and CTFs forms has been described elsewhere. 22 Overall, 5-ALA administration did not exert a quantitative effect on the levels of APP, APP CTFs, BACE1, and PS1 CTF.
Third, we examined brain Aβ levels in the brain region encompassing the hippocampus and cerebral cortex. Because the level of CTFβ, the precursor of Aβ40 and Aβ42, differed slightly between males and females, we measured Aβ40 and Aβ42 separately in male and female mice (Fig. 4) . In both males (panel A) and females (panel B), Aβ40 (left) tended to decrease in 5-ALA-fed mice compared to controls; however, we did not perform statistical analysis because of the small number of mice examined (two 5-ALA-fed males and two control-fed females) ( Fig. 4A left and B left) . The Aβ42 level (right) also decreased in males, but not in females ( Fig. 4A right and B right) . Importantly, the Aβ levels differed between female and male 3xTg mice (4-5-fold for Aβ40 and ~20-fold for Aβ42) regardless of 5-ALA administration. Therefore, to determine the statistical significance of differences in Aβ levels, we compared relative brain Aβ levels in all mice examined; for this comparison, the Aβ level of control mice brain was set at 1.0 (Fig. 4C) . The Aβ40 level decreased significantly in 5-ALA-fed brain (Fig. 4C left) , but no significant difference was observed for Aβ42.
It may not be possible to explain the higher accumulation of brain Aβ in female mice relative to male mice (4-5-folds for Aβ40, ~ 20-fold for Aβ42) based solely on the slightly higher levels of CTFβ in females (~1.5 fold) (Figs. 2 and 3D) .
Instead, the levels of the transgene products may also be influenced by sex-specific differences in APP metabolism.
The 3xTg-AD model mice exhibited higher levels of Aβ accumulation in the female brain, and the Aβ40 level was high in control mice relative to 5-ALA-fed mice ( Fig. 4B and C) . As noted above, 3xTg-AD mice exhibit Aβ deposition at 6 months of age 12 and they accumulate pTau in the hippocampus with age. (Fig. 5) . Contrary to expectations, we did not detect obvious amyloid plaques in either control or 5-ALA fed mice using any of the three antibodies, although we observed strong Aβ signals within the neurons of the cortex, hippocampus, and amygdala ( Fig. 5A-C; typical staining is indicated by the arrow in panel B), as previously reported.
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According to expectation, no pTau staining was observed using the AT8 antibody ( Fig.   5D ), consistent with a previous report showing that AT8 detects pTau in the hippocampus of 17-month-old mice. 23 We observed no marked differences between 5-ALA-fed mice and control animals (at an age of 9 months) with respect to Aβ and pTau immunostaining, although 5-ALA-fed mice did exhibit reduced Aβ accumulation in the brain (Fig. 4C) . . 10 This dysfunction was remarkable in that it was specific to mitochondria in synaptosomes, rather than all mitochondria in the brain.
Discussion
We sought to determine whether oral administration of 5-ALA is effective in suppressing AD-related pathobiology, such as amyloidogenic processing of APP, accumulation of Aβ and pTau in the brain, and the reduction in synapses or synaptic proteins. 29, 30 We observed that APP CTFβ and Aβ levels were clearly higher in female mice than in males; however, levels of APP FL expression and CTFα generation were comparable between male and female mice. Therefore, we analyzed male and female samples separately. When compared relative brain Aβ levels in all mice examined, the Aβ40 level decreased significantly in 5-ALA-fed mice. Contrary to expectation, we did not detect any AD pathology, including Aβ plaques, in control or 5-ALA-fed mice of either sex at the age of 9 months. Thus, the effect of 5-ALA to AD pathology could not be examined at this age. To analyze AD pathobiology, we may need to conduct longer-term experiments in older mice.
Recent studies report that synaptic impairment occurs prior to the onset of AD pathology, and that this phenomenon is induced by Aβ oligomers. 18, 29 We observed significantly higher levels of synaptotagmin in 5-ALA-fed mice than in controls.
However, levels of the synaptic protein PSD95 and various subunits of the NMDA and AMPA receptors did not change significantly following 5-ALA administration. The slight effect on synaptotagmin suggests that 5-ALA exerts a slight preservative effect on synapses prior to the onset of AD pathology; however, we need to perform further studies involving alternative aged AD mouse models and longer-term administration of 5-ALA to confirm this effect. Furthermore, as suggested by a recent report, 10 analysis of the synaptosomal fraction may reveal clearer effects of 5-ALA on the preservation of synaptic proteins.
Finally, we wish to propose a possible mechanism by which preservation of mitochondrial function could slow Aβ-induced neuronal impairment in AD. Neurons have long axons and highly branched dendrites, which are supported functionally and architecturally by a well-organized membrane, cytoskeletal components such as microtubules, and molecular motor proteins carrying membrane cargos and mitochondria. 31 Dysfunction of intraneuronal transport causes neurodegeneration.
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Interestingly, APP, the precursor of neurotoxic Aβ, plays an important role as a cargo of kinesin-1, which is composed of two kinesin light chains and two kinesin heavy chains (KHCs). 
